purchase customization

Leave This Empty:

choose chapter to purchase

table of content

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Non-muscle Invasive Bladder Cancer Therapeutics
1.2 Key Market Segments
1.2.1 Non-muscle Invasive Bladder Cancer Therapeutics Segment by Type
1.2.2 Non-muscle Invasive Bladder Cancer Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Non-muscle Invasive Bladder Cancer Therapeutics Market Overview
2.1 Global Market Overview
2.1.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Non-muscle Invasive Bladder Cancer Therapeutics Market Competitive Landscape
3.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Sales by Manufacturers (2019-2024)
3.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Manufacturers (2019-2024)
3.3 Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Non-muscle Invasive Bladder Cancer Therapeutics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Non-muscle Invasive Bladder Cancer Therapeutics Sales Sites, Area Served, Product Type
3.6 Non-muscle Invasive Bladder Cancer Therapeutics Market Competitive Situation and Trends
3.6.1 Non-muscle Invasive Bladder Cancer Therapeutics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Non-muscle Invasive Bladder Cancer Therapeutics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Non-muscle Invasive Bladder Cancer Therapeutics Industry Chain Analysis
4.1 Non-muscle Invasive Bladder Cancer Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Non-muscle Invasive Bladder Cancer Therapeutics Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Non-muscle Invasive Bladder Cancer Therapeutics Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Type (2019-2024)
6.3 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Market Share by Type (2019-2024)
6.4 Global Non-muscle Invasive Bladder Cancer Therapeutics Price by Type (2019-2024)
7 Non-muscle Invasive Bladder Cancer Therapeutics Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Sales by Application (2019-2024)
7.3 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size (M USD) by Application (2019-2024)
7.4 Global Non-muscle Invasive Bladder Cancer Therapeutics Sales Growth Rate by Application (2019-2024)
8 Non-muscle Invasive Bladder Cancer Therapeutics Market Segmentation by Region
8.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Sales by Region
8.1.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Sales by Region
8.1.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Region
8.2 North America
8.2.1 North America Non-muscle Invasive Bladder Cancer Therapeutics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Non-muscle Invasive Bladder Cancer Therapeutics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Non-muscle Invasive Bladder Cancer Therapeutics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Non-muscle Invasive Bladder Cancer Therapeutics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Non-muscle Invasive Bladder Cancer Therapeutics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 F. Hoffmann-La Roche Ltd.
9.1.1 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.1.2 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.1.3 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.1.4 F. Hoffmann-La Roche Ltd. Business Overview
9.1.5 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics SWOT Analysis
9.1.6 F. Hoffmann-La Roche Ltd. Recent Developments
9.2 Bristol-Myers Squibb Company
9.2.1 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.2.2 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.2.3 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.2.4 Bristol-Myers Squibb Company Business Overview
9.2.5 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics SWOT Analysis
9.2.6 Bristol-Myers Squibb Company Recent Developments
9.3 AstraZeneca
9.3.1 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.3.2 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.3.3 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.3.4 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics SWOT Analysis
9.3.5 AstraZeneca Business Overview
9.3.6 AstraZeneca Recent Developments
9.4 Pfizer Inc.
9.4.1 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.4.2 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.4.3 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.4.4 Pfizer Inc. Business Overview
9.4.5 Pfizer Inc. Recent Developments
9.5 GlaxoSmithKline plc.
9.5.1 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.5.2 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.5.3 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.5.4 GlaxoSmithKline plc. Business Overview
9.5.5 GlaxoSmithKline plc. Recent Developments
9.6 Sanofi S.A.
9.6.1 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.6.2 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.6.3 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.6.4 Sanofi S.A. Business Overview
9.6.5 Sanofi S.A. Recent Developments
9.7 Novartis AG
9.7.1 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.7.2 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.7.3 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.7.4 Novartis AG Business Overview
9.7.5 Novartis AG Recent Developments
9.8 Eli Lilly and Company
9.8.1 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.8.2 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.8.3 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.8.4 Eli Lilly and Company Business Overview
9.8.5 Eli Lilly and Company Recent Developments
9.9 Merck and Co.
9.9.1 Merck and Co. Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.9.2 Merck and Co. Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.9.3 Merck and Co. Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.9.4 Merck and Co. Business Overview
9.9.5 Merck and Co. Recent Developments
9.10 Viventia Bio Inc.
9.10.1 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.10.2 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.10.3 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.10.4 Viventia Bio Inc. Business Overview
9.10.5 Viventia Bio Inc. Recent Developments
9.11 Celgene Corporation
9.11.1 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.11.2 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.11.3 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.11.4 Celgene Corporation Business Overview
9.11.5 Celgene Corporation Recent Developments
9.12 Spectrum Pharmaceuticals, Inc.
9.12.1 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.12.2 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.12.3 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.12.4 Spectrum Pharmaceuticals, Inc. Business Overview
9.12.5 Spectrum Pharmaceuticals, Inc. Recent Developments
9.13 Herantis Pharma Plc.
9.13.1 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.13.2 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.13.3 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.13.4 Herantis Pharma Plc. Business Overview
9.13.5 Herantis Pharma Plc. Recent Developments
9.14 Taris Biomedical LLC
9.14.1 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.14.2 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.14.3 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.14.4 Taris Biomedical LLC Business Overview
9.14.5 Taris Biomedical LLC Recent Developments
9.15 Prometic Life Sciences Inc.
9.15.1 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.15.2 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.15.3 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.15.4 Prometic Life Sciences Inc. Business Overview
9.15.5 Prometic Life Sciences Inc. Recent Developments
9.16 Telormediz S.A.
9.16.1 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.16.2 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.16.3 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.16.4 Telormediz S.A. Business Overview
9.16.5 Telormediz S.A. Recent Developments
9.17 Heat Biologics
9.17.1 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.17.2 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.17.3 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.17.4 Heat Biologics Business Overview
9.17.5 Heat Biologics Recent Developments
9.18 Altor BioScience
9.18.1 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.18.2 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.18.3 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.18.4 Altor BioScience Business Overview
9.18.5 Altor BioScience Recent Developments
9.19 Ferring B.V.
9.19.1 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.19.2 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.19.3 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.19.4 Ferring B.V. Business Overview
9.19.5 Ferring B.V. Recent Developments
9.20 Cold Genesys Inc.
9.20.1 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Basic Information
9.20.2 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Overview
9.20.3 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Market Performance
9.20.4 Cold Genesys Inc. Business Overview
9.20.5 Cold Genesys Inc. Recent Developments
10 Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast by Region
10.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Forecast
10.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size Forecast by Country
10.2.3 Asia Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size Forecast by Region
10.2.4 South America Non-muscle Invasive Bladder Cancer Therapeutics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Non-muscle Invasive Bladder Cancer Therapeutics by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Non-muscle Invasive Bladder Cancer Therapeutics by Type (2025-2030)
11.1.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Non-muscle Invasive Bladder Cancer Therapeutics by Type (2025-2030)
11.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast by Application (2025-2030)
11.2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Sales (K Units) Forecast by Application
11.2.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings